This leads to a tumor microenvironment that is inflamed by T cells, with more cytotoxic T lymphocytes getting into the tumor, which synergizes with PD-1/PD-L1 antibodies to give better tumor suppression. This evidence concerns the gene PDCD1 and neoplasm.